Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioMarin Pharmaceutical
Pharma
DOJ probing BioMartin testing programs for Vimizim, Naglazyme
BioMarin has provided documents to the DoJ in response to a subpoena which requested information on the company’s programs for Vimizim and Naglazyme.
Kevin Dunleavy
Feb 28, 2024 7:48am
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
Feb 23, 2024 10:15am
BioMarin’s commercial chief Jeffrey Ajer hits the exit
Jan 12, 2024 10:28am
JPM24, Day 3: CRISPR, BioMarin, Alkermes and more
Jan 10, 2024 7:00pm
JPM24: New BioMarin CEO Hardy makes his priorities clear
Jan 10, 2024 11:29am
BioMarin settles with Elliott, adds new directors, review committee
Dec 21, 2023 10:50am